B.R.A.I.N. Biotechnology Research and Information Network AG (GB:0RFI)
LSE:0RFI
Want to see GB:0RFI full AI Analyst Report?
0RFI Stock Chart & Stats
€2.49
-€0.04(-1.13%)
At close: 4:00 PM EST
€2.49
-€0.04(-1.13%)
Day’s Range― - ―
52-Week Range€1.81 - €3.90
Previous CloseN/A
Volume57.99K
Average Volume (3M)6.32K
Market Cap
€65.76M
Enterprise Value€120.74M
Total Cash (Recent Filing)€6.32M
Total Debt (Recent Filing)€24.03M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
May 28, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding21,847,494
10 Day Avg. Volume6,862
30 Day Avg. Volume6,320
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.00Price Target Upside100.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)€57.02M
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementAn improving gross margin signals better cost control or a more favorable product mix. If sustained, higher gross margins create structural room to invest in R&D or absorb operating costs, supporting a path toward profitability even while operating losses persist.
Free Cash Flow ImprovementA reduction in negative free cash flow, even from a negative base, reduces near-term external funding pressure. Continued improvement would lengthen the company’s runway, lowering refinancing frequency and giving management more flexibility to execute strategic R&D and commercialization steps.
Established WorkforceA near-300-person workforce indicates retained operational and scientific capacity, supporting ongoing R&D and regulatory work. Maintaining skilled staff is a durable asset for biotech firms, preserving institutional knowledge and the ability to advance pipelines over multiple quarters.
Bears Say
Persistent Net LossesOngoing net losses and continued cash burn are structural headwinds that erode equity and force repeated capital raises. Persistent unprofitability undermines long-term viability unless offset by clear progress toward commercial revenue or sustained margin expansion.
Declining RevenueConsecutive years of revenue decline indicate weakening top-line momentum and reduce leverage of fixed R&D and G&A spend. Without reversing revenue trends, the company faces tougher trade-offs between funding growth, preserving cash, and avoiding further dilution.
Heightened Balance-sheet LeverageA steep drop in equity and higher debt-to-equity increases refinancing and dilution risk. Elevated leverage reduces financial flexibility, raises funding costs, and can constrain the company’s ability to fund trials or commercialization without materially dilutive raises or costly borrowing.
0RFI FAQ
What was B.R.A.I.N. Biotechnology Research and Information Network AG’s price range in the past 12 months?
B.R.A.I.N. Biotechnology Research and Information Network AG lowest share price was €1.81 and its highest was €3.90 in the past 12 months.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap?
B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap is €65.76M.
When is B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date?
B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date is May 28, 2026 which is in 5 days.
How were B.R.A.I.N. Biotechnology Research and Information Network AG’s earnings last quarter?
Currently, no data Available
Is B.R.A.I.N. Biotechnology Research and Information Network AG overvalued?
According to Wall Street analysts B.R.A.I.N. Biotechnology Research and Information Network AG’s price is currently Undervalued.
Does B.R.A.I.N. Biotechnology Research and Information Network AG pay dividends?
B.R.A.I.N. Biotechnology Research and Information Network AG does not currently pay dividends.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate?
B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate is -0.09.
How many shares outstanding does B.R.A.I.N. Biotechnology Research and Information Network AG have?
B.R.A.I.N. Biotechnology Research and Information Network AG has 21,847,494 shares outstanding.
What happened to B.R.A.I.N. Biotechnology Research and Information Network AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of B.R.A.I.N. Biotechnology Research and Information Network AG?
Currently, no hedge funds are holding shares in GB:0RFI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
B.R.A.I.N. Biotechnology Research and Information Network Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-337.77%
Trailing 12-Months
Asset Growth
-25.24%
Trailing 12-Months
Company Description
B.R.A.I.N. Biotechnology Research and Information Network AG
BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.
B.R.A.I.N. Biotechnology Research and Information Network (0RFI) Earnings & Revenues
0RFI Stock 12 Month Forecast
Average Price Target
€5.00
▲(100.80% Upside)